Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors
Study Details
Study Description
Brief Summary
Safety study of ABT-263 in Combination with Paclitaxel in Subjects with Solid Tumors.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Detailed Description
A Phase 1 Safety and Pharmacokinetic Study of ABT-263 in Combination with Paclitaxel in the Treatment of Subjects with Solid Tumors.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Paclitaxel and ABT-263
|
Drug: ABT-263
150 mg of ABT-263 is taken orally once daily on Days 1-3 out of each 21 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
Other Names:
Drug: paclitaxel
175 mg/m2 over 3 hours of paclitaxel will be given by intravenous infusion on Day 1 of each 21 day cycle.
Note - The dose and schedule is subject to change based on the toxicities observed.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Safety Assessment [Weekly]
Evaluate safety at the defined recommended Phase 2 dose (RPTD) and schedule of ABT-263 in combination with Paclitaxel
- Efficacy Assessment [Bi-monthly]
Evaluate preliminary data regarding objective response rate (ORR), progression free survival (PFS), time to tumor progression (TTP), overall survival (OS), duration of overall response, and, ECOG performance status
Eligibility Criteria
Criteria
Inclusion Criteria
-
Subject must be greater than or equal to 18 years of age.
-
Subject must have a histologically and/or cytologically documented cancer for which paclitaxel has been determined an appropriate therapy, per the Investigator.
-
Subjects with brain metastases must have clinically controlled neurologic symptoms, defined as surgical excision and/or radiation therapy followed by 21 days of stable neurologic function and no evidence of CNS disease progression as determined by CT or MRI within 28 days prior to the first dose of study drug.
-
Subject has an Eastern Cooperative Oncology Group (ECOG) score of less than or equal to 1.
-
Subject must have adequate bone marrow, renal and hepatic function per protocol defined local laboratory testing parameters.
Exclusion Criteria
-
The subject has an underlying, predisposing condition of bleeding or currently exhibits signs of bleeding. The subject has a recent history of thrombocytopenia associated with bleeding within 1 year prior to first dose of study drug.
-
Subject is currently receiving or requires anticoagulation therapy (e.g., warfarin at any dose) or any drugs or herbal supplements that affect platelet function, with the exception of low-dose anticoagulation medications such as heparin that are used to maintain the patency of a central intravenous catheter.
-
The subject has active peptic ulcer disease or other potentially hemorrhagic esophagitis/gastritis.
-
The subject has active immune thrombocytopenic purpura (ITP), autoimmune hemolytic anemia (AIHA), or a history of being refractory to platelet transfusions (within 1 year prior to the first dose of study drug).
-
The subject has a significant history of cardiovascular (e.g., MI, thrombotic or thromboembolic event in the last 6 months), renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, or hepatic disease that in the opinion of the investigator would adversely affect his/her participating in this study.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- AbbVie
- Genentech, Inc.
Investigators
- Study Director: Mack Mabry, MD, Abbott
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- M10-589